PDLabs is a compounding and research pharmacy established in 1998 to research and develop new indications for existing medications and to develop new drug delivery systems. PDLabs’ most significant discovery and contribution to pharmacotherapy to date relates to the use of calcium channel blockers for the non-invasive, topically applied transdermal treatment of connective tissue disorders such as Peyronie’s disease, Dupuytren’s disease and plantar fibromatosis.